Il levetiracetam nel trattamento dell'epilessia mioclonica giovanile

Translated title of the contribution: Levetiracetam in the treatment of juvenile myoclonic epilepsy

G. Boero, N. Specchio, A. Gambardella, A. T. Giallonardo, R. Michelucci, J. Fattouch, C. Di Bonaventura, A. La Neve, L. M. Specchio

Research output: Contribution to journalArticle

Abstract

The aim of this multicentre, prospective, open-label, pragmatic study is to evaluate the effectiveness of levetiracetam (LEV) in juvenile myoclonic epilepsy (JME), LEV was given (up to 3000 mg/day) as add-on treatment in JME patients resistant or intolerant to previous AEDs, or as first treatment in newly diagnosed patients. 43 patients were enrolled (35 F); 8 were newly diagnosed. Mean dosage of LEV was 2090 mg/day (± 784). Mean study period was 18 months (± 10). 16/43 (37%) patients were seizure-free, 18/43 (41%) were without mioclonias, and 30/43 (69%) had no GTC seizures. Mean monthly frequencies of days with mioclonias and generalized tonic-clonic seizures before and after LEV were 5.9 ± 6.4 vs 2.1 ± 5.5 (p = 0.004), and 0.5 ± 0.9 vs 0.2 ± 0.6 respectively. 5/10 patients showed a suppression or a marked reduction of photosensitivity. 5 patients complained of side effects. In our study LEV appears to be useful and well-tolerated in the treatment of JME.

Original languageItalian
Pages (from-to)101-103
Number of pages3
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number129-130
Publication statusPublished - 2005

Fingerprint

etiracetam
Juvenile Myoclonic Epilepsy
Seizures
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Boero, G., Specchio, N., Gambardella, A., Giallonardo, A. T., Michelucci, R., Fattouch, J., ... Specchio, L. M. (2005). Il levetiracetam nel trattamento dell'epilessia mioclonica giovanile. Bollettino - Lega Italiana contro l'Epilessia, (129-130), 101-103.

Il levetiracetam nel trattamento dell'epilessia mioclonica giovanile. / Boero, G.; Specchio, N.; Gambardella, A.; Giallonardo, A. T.; Michelucci, R.; Fattouch, J.; Di Bonaventura, C.; La Neve, A.; Specchio, L. M.

In: Bollettino - Lega Italiana contro l'Epilessia, No. 129-130, 2005, p. 101-103.

Research output: Contribution to journalArticle

Boero, G, Specchio, N, Gambardella, A, Giallonardo, AT, Michelucci, R, Fattouch, J, Di Bonaventura, C, La Neve, A & Specchio, LM 2005, 'Il levetiracetam nel trattamento dell'epilessia mioclonica giovanile', Bollettino - Lega Italiana contro l'Epilessia, no. 129-130, pp. 101-103.
Boero, G. ; Specchio, N. ; Gambardella, A. ; Giallonardo, A. T. ; Michelucci, R. ; Fattouch, J. ; Di Bonaventura, C. ; La Neve, A. ; Specchio, L. M. / Il levetiracetam nel trattamento dell'epilessia mioclonica giovanile. In: Bollettino - Lega Italiana contro l'Epilessia. 2005 ; No. 129-130. pp. 101-103.
@article{a2c71b1701c44961936f76fae8f0f6ed,
title = "Il levetiracetam nel trattamento dell'epilessia mioclonica giovanile",
abstract = "The aim of this multicentre, prospective, open-label, pragmatic study is to evaluate the effectiveness of levetiracetam (LEV) in juvenile myoclonic epilepsy (JME), LEV was given (up to 3000 mg/day) as add-on treatment in JME patients resistant or intolerant to previous AEDs, or as first treatment in newly diagnosed patients. 43 patients were enrolled (35 F); 8 were newly diagnosed. Mean dosage of LEV was 2090 mg/day (± 784). Mean study period was 18 months (± 10). 16/43 (37{\%}) patients were seizure-free, 18/43 (41{\%}) were without mioclonias, and 30/43 (69{\%}) had no GTC seizures. Mean monthly frequencies of days with mioclonias and generalized tonic-clonic seizures before and after LEV were 5.9 ± 6.4 vs 2.1 ± 5.5 (p = 0.004), and 0.5 ± 0.9 vs 0.2 ± 0.6 respectively. 5/10 patients showed a suppression or a marked reduction of photosensitivity. 5 patients complained of side effects. In our study LEV appears to be useful and well-tolerated in the treatment of JME.",
keywords = "Juvenile Myoclonic Epilepsy, Levetiracetam, Open-label study",
author = "G. Boero and N. Specchio and A. Gambardella and Giallonardo, {A. T.} and R. Michelucci and J. Fattouch and {Di Bonaventura}, C. and {La Neve}, A. and Specchio, {L. M.}",
year = "2005",
language = "Italian",
pages = "101--103",
journal = "Bollettino - Lega Italiana contro l'Epilessia",
issn = "0394-560X",
publisher = "Lega Italiana contro l'Epilessia",
number = "129-130",

}

TY - JOUR

T1 - Il levetiracetam nel trattamento dell'epilessia mioclonica giovanile

AU - Boero, G.

AU - Specchio, N.

AU - Gambardella, A.

AU - Giallonardo, A. T.

AU - Michelucci, R.

AU - Fattouch, J.

AU - Di Bonaventura, C.

AU - La Neve, A.

AU - Specchio, L. M.

PY - 2005

Y1 - 2005

N2 - The aim of this multicentre, prospective, open-label, pragmatic study is to evaluate the effectiveness of levetiracetam (LEV) in juvenile myoclonic epilepsy (JME), LEV was given (up to 3000 mg/day) as add-on treatment in JME patients resistant or intolerant to previous AEDs, or as first treatment in newly diagnosed patients. 43 patients were enrolled (35 F); 8 were newly diagnosed. Mean dosage of LEV was 2090 mg/day (± 784). Mean study period was 18 months (± 10). 16/43 (37%) patients were seizure-free, 18/43 (41%) were without mioclonias, and 30/43 (69%) had no GTC seizures. Mean monthly frequencies of days with mioclonias and generalized tonic-clonic seizures before and after LEV were 5.9 ± 6.4 vs 2.1 ± 5.5 (p = 0.004), and 0.5 ± 0.9 vs 0.2 ± 0.6 respectively. 5/10 patients showed a suppression or a marked reduction of photosensitivity. 5 patients complained of side effects. In our study LEV appears to be useful and well-tolerated in the treatment of JME.

AB - The aim of this multicentre, prospective, open-label, pragmatic study is to evaluate the effectiveness of levetiracetam (LEV) in juvenile myoclonic epilepsy (JME), LEV was given (up to 3000 mg/day) as add-on treatment in JME patients resistant or intolerant to previous AEDs, or as first treatment in newly diagnosed patients. 43 patients were enrolled (35 F); 8 were newly diagnosed. Mean dosage of LEV was 2090 mg/day (± 784). Mean study period was 18 months (± 10). 16/43 (37%) patients were seizure-free, 18/43 (41%) were without mioclonias, and 30/43 (69%) had no GTC seizures. Mean monthly frequencies of days with mioclonias and generalized tonic-clonic seizures before and after LEV were 5.9 ± 6.4 vs 2.1 ± 5.5 (p = 0.004), and 0.5 ± 0.9 vs 0.2 ± 0.6 respectively. 5/10 patients showed a suppression or a marked reduction of photosensitivity. 5 patients complained of side effects. In our study LEV appears to be useful and well-tolerated in the treatment of JME.

KW - Juvenile Myoclonic Epilepsy

KW - Levetiracetam

KW - Open-label study

UR - http://www.scopus.com/inward/record.url?scp=33645216335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645216335&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:33645216335

SP - 101

EP - 103

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 129-130

ER -